SCHEMBL4813356

SCHEMBL4813356

CCn1nc(Cc2ccc(C(=O)NCc3cccnc3)cc2-c2ccc(Cl)cc2C(=O)O)c2ccc(C(=N)N)cc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.45
PIK3CA P42336 3/20 0.44
PPARG P37231 1/20 0.42
DGAT2 Q96PD7 1/20 0.41
EIF4E P06730 1/20 0.41
PTGER1 P34995 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
USP2 O75604 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
DRD2 P14416 2/20 0.39
DRD3 P35462 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811754 0.93 PIK3CA (0.46) ROCK2PIK3CAPPARGDGAT2ALDH1A1
SCHEMBL4810537 0.91 ROCK2 (0.46) ROCK2PIK3CAALDH1A1GAAF2
SCHEMBL4815003 0.82 ALDH1A1 (0.38) ROCK2PIK3CAALDH1A1F2F10
SCHEMBL4812948 0.80 F2 (0.43) ROCK2PPARGDGAT2ALDH1A1GAA
SCHEMBL4812866 0.80 PIK3CA (0.44) ROCK2PIK3CAPPARGALDH1A1GAA
SCHEMBL4809282 0.79 P2RX3 (0.43) ALDH1A1F2F10F7F3
SCHEMBL4811035 0.79 ROCK2 (0.47) ROCK2PIK3CAALDH1A1GAAF2
SCHEMBL4806024 0.77 F2 (0.41) ROCK2ALDH1A1F2F10F7
SCHEMBL4813372 0.74 EIF4E (0.41) ROCK2PPARGEIF4EPTGER1ALDH1A1
SCHEMBL4816068 0.74 SLC22A12 (0.39) F2F10F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US claimed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 ROCK2 1511/4885PIK3CA 555/4885PPARG 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.